Piramal Pharma discloses successful closure of US FDA inspection at its Lexington, USA facility.
US FDA issued an EIR with Voluntary Action Indicated (VAI) status for the facility.
The disclosure is made under SEBI LODR Regulation 30 on the first working day after EIR receipt.